Novel Approaches to Diagnosis and Treatment of Antibody Rejection 2021

100 Terranea Way,Rancho Palos Verdes CA 90275

25 September, 2021

Description

. One of the most important problems in transplantation today is controlling allo-immune responses to transplanted organs that result in antibody mediated rejection with subsequent graft loss. In the United States, approximately 5,000 grafts fail each year with the majority due to chronic antibody rejection. Patients returning to the transplant list after allograft failure now comprise the fourth largest category of patients listed and create difficulties for organ allocation as most are highly sensitized. In this symposium we will address the current state of therapy for antibody mediated injury to allografts as well as newer protocols utilizing novel immune-modulatory drugs (imlifidase, Anti-IL-6, FCRN, receptor blocker and antibodies to plasma cells, costimulatory blockade and complement inhibitors) as promising agents for prevention and treatment of antibody rejecton. In addition, Dr. Alex Loupy will discuss the application of artificial intelligence to management of sensitized transplant recipients and how this will aid in new drug development, non-invasive diagnostics, especially measurement of donor derived cell free DNA. This is critical given the growing interest in development of novel immune-modulatory drugs and therapeutic approaches that are more specific with less side effects and expense. This one day educational symposium is designed to help attendees understand the current and future directions of immune-modulatory therapy for treatment of antibody mediated rejection. Evolving diagnostic techniques to monitor patients for evidence of ABMR and response to treatment. Discussions will focus on in depth analysis of efficacy and side effect profiles that will improve care.